- Phase 1
- Phase 2
- Phase 3
- NDA Filed
Approved for Use
In November of 2018, DSUVIA was approved by the U.S. Food and Drug Administration.
To learn more about DSUVIA, please visit DSUVIA.com.
DSUVIA was divested to Alora Pharmaceuticals in April 2023. AcelRx will receive a 15% royalty on commercial net sales, 75% royalty on net sales to the Department of Defense, and up to $116.5 million in milestone payments.